Last reviewed · How we verify
Alogliptin and pioglitazone — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Alogliptin and pioglitazone (Alogliptin and pioglitazone) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Alogliptin and pioglitazone TARGET | Alogliptin and pioglitazone | Takeda | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Alogliptin and pioglitazone CI watch — RSS
- Alogliptin and pioglitazone CI watch — Atom
- Alogliptin and pioglitazone CI watch — JSON
- Alogliptin and pioglitazone alone — RSS
Cite this brief
Drug Landscape (2026). Alogliptin and pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/alogliptin-and-pioglitazone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab